Why Is Turning Point Brands (TPB) Stock Down -9.01% Today?
Key Takeaways
- Shares of Turning Point Brands (TPB) fell roughly 9% in early trading Monday, sliding from a prior close of $68.14 to about $62.00.
- Primary catalyst: The company announced that Chief Executive Officer Graham Purdy is stepping down for personal reasons, with Executive Chairman David E. Glazek taking over as CEO.
- Secondary driver: Management tightened its full-year 2026 EBITDA guidance range to $70–$80 million, down from $70–$90 million, citing higher freight costs and delayed onshoring benefits.
- Broader context: The move adds to a difficult stretch for the stock, which has been pressured by regulatory uncertainty around FDA approval of nicotine pouches.
- What to watch: Investors are now focused on the leadership transition, execution of the Modern Oral growth strategy, and third-quarter results expected in early November.
Opening Summary
Turning Point Brands, Inc. (TPB) is a Louisville, Kentucky-based manufacturer and distributor of branded consumer products, best known for its Zig-Zag rolling papers and Stoker's moist snuff, along with its fast-growing FRE and ALP nicotine pouch brands. The stock dropped sharply in Monday's session, falling about 9.01% to trade near $62.00, down from Friday's closing price of $68.14. The decline followed a pair of corporate announcements: a surprise CEO transition and a downward revision to the low end of the company's profitability guidance.
Executive Leadership Change
The most immediate trigger for the sell-off was news that Chief Executive Officer Graham Purdy is stepping down effective October 1, 2026, citing personal reasons. The company said the departure is not related to any disagreement with the board. Executive Chairman David E. Glazek, who has been involved with the company for roughly 12 years, will assume the CEO role.
Sudden leadership transitions in growth-stage companies often rattle investors, particularly when they involve a departing CEO who oversaw the rapid expansion of a strategically important segment. Mr. Purdy had guided TPB through the early rollout of its Modern Oral nicotine pouch business, a category that now accounts for a substantial and growing share of revenue. The unexpected nature of the announcement removed a layer of management continuity that markets had priced into the stock.
Guidance Revisions and Margin Concerns
Compounding the leadership news, the company updated its financial outlook in the same release. Management reaffirmed its full-year 2026 Modern Oral gross sales guidance of $330 million to $350 million and net sales guidance of $260 million to $270 million. However, it tightened its full-year EBITDA guidance to a range of $70 million to $80 million, down from the prior $70 million to $90 million.
The revision reflects two specific pressures management called out: an expectation of no margin benefit from shifting manufacturing onshore until 2027, and prolonged, elevated freight costs. By lowering the top end of its EBITDA range, the company signaled that near-term profitability will come in weaker than previously anticipated, even as its top-line trajectory remains intact. That combination—strong sales growth paired with compressed margins—was enough to prompt a reassessment of the stock's valuation.
Regulatory Overhang on Nicotine Pouches
The sell-off also arrives against a backdrop of broader regulatory uncertainty. TPB has leaned heavily on its Modern Oral segment, led by the FRE and ALP brands, for growth. In recent weeks, the stock has been pressured by reports that the U.S. Food and Drug Administration has been hesitant to authorize new oral nicotine pouch products, citing concerns about health effects and youth usage. Any slowdown in the regulatory approval pipeline carries direct implications for product rollout plans and long-term category expansion, keeping sentiment fragile in the tobacco-alternatives space.
Market Context and Trading Activity
The stock gapped down at the open, with early prints around $61.77 compared with Friday's $68.14 close, indicating sellers acted quickly in response to the dual announcements. The decline extends a challenging stretch for shares, which have fallen sharply from their 52-week highs near $147 and remain well below their 50-day and 200-day moving averages.
The move is largely company-specific rather than reflective of a broader market or sector swing. While TPB shares plunged on their own news, the reaction highlights how sensitive a growth narrative built on Modern Oral expansion can be to management stability and margin visibility, even in the absence of a top-line disappointment.
What Comes Next for TPB
Looking ahead, investors will be watching the October 1 leadership transition closely, as well as any further color on how the new CEO intends to execute the Modern Oral growth strategy and manage costs. The company's next quarterly earnings report is expected in early November, which should provide an update on pouch sales trends, margin trajectory, and the pace of onshoring efforts.
Key risks include continued regulatory scrutiny from the FDA, competitive pressure in the rapidly growing nicotine pouch category from larger tobacco rivals, and the possibility that freight-cost and onshoring headwinds persist longer than expected. Any reversal in the regulatory environment or faster-than-anticipated margin recovery could equally shift the narrative, leaving the stock's near-term direction closely tied to execution and external policy developments.
Trending AI Robots
For traders seeking a data-driven edge in fast-moving markets, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing automated strategies. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a range of approaches to explore. Discover which AI-driven strategies are currently leading the pack by visiting the Trending AI Robots page today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for TPB turns negative, indicating new downward trend
TPB saw its Momentum Indicator move below the 0 level on August 27, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned negative. In 52 of the 77 cases, the stock moved further down in the following days. The odds of a decline are at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TPB turned negative on August 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 25 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
TPB moved below its 50-day moving average on August 31, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TPB crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for TPB entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where TPB advanced for three days, in 231 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
TPB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.177) is normal, around the industry mean (16.593). P/E Ratio (29.626) is within average values for comparable stocks, (20.104). Projected Growth (PEG Ratio) (0.048) is also within normal values, averaging (3.706). TPB has a moderately low Dividend Yield (0.005) as compared to the industry average of (0.036). P/S Ratio (2.701) is also within normal values, averaging (2.780).
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock worse than average.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. TPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of tobacco products
Industry Tobacco
Advertisement